IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Showing posts with label Hyperion Therapeutics. Show all posts
Showing posts with label Hyperion Therapeutics. Show all posts
Friday, 12 September 2014

When clinical trial data is fudged; woe to the company or woe to the industry?

›
When I think of clinical test data, my attention is usually drawn to controversial Article 39.3 of the TRIPS Agreement, which affords prot...
2 comments:
›
Home
View web version
Powered by Blogger.